Table 3.

Prospective clinical trials of second-line chemotherapy of esophageal cancer

Design	Treatment	n	RR	Median OS	Reference
Phase II	Vinorelbine	16+	6%	6 months	88
Phase II	Docetaxel	11++	0%	4 months	89
Phase II	Docetaxel/irinotecan	24+++	12.5%	6.5 months	94
Phase II	Paclitaxel	13+++	0%	NA	91
Phase II	Docetaxel	38+++	16%	8.1 months	90
Phase II	Docetaxel/capecitabine	8+++	25%	6.2 months	54
Phase II	Docetaxel/nedaplatin	28+++	39.3%	8.5 months	100
Phase II	Docetaxel/nedaplatin	12+	25%	NA	97
Phase II	Irinotecan	13++	15.4%	5 months	92
Phase II	Docetaxel/cisplatin/5-FU	20+++	35%	8 months	101
Phase II	Docetaxel/cisplatin/5-FU	32+++	50%	NA	102
Phase II	Mitomycin/ifosfamide/cisplatin	19+	12.5%	5.2 months	103
Phase II	Docetaxel/nedaplatin	20+	25%	6.5 months	98
Phase II	Docetaxel/irinotecan	15++	20%	11.4 months	95
Phase II	Docetaxel/nedaplatin	46+	27.1%	5.9 months	99
Phase II	Docetaxel/cisplatin	35+	34.2%	7.4 months	96
Phase III	Docetaxel	84#	7%#	5.2 months#,*	93
	BSC	84#	0%#	3.6 months#

Notes:

^*P < 0.05;

⁺squamous cell carcinoma;

⁺⁺adenocarcinoma;

⁺⁺⁺squamous cell carcinoma/adenocarcinoma;

^#including stomach cancer.

Abbreviations: 5-FU, 5-fluorouracil; RR, response rate; OS, overall survival; NA, nonapplicable; BSC, best supportive care.